NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative ...
The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of CALR mutations in mid-2026, following alignment with regulators ...
INCA033989 targets mutCALR, showing hematologic responses in 80% of ET patients and anemia responses in 36% of MF patients. The study employed next-generation sequencing, multi-omic analysis, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results